Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282215 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
A Phase 2 study, sponsored by Cellerant Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT02282215 is a Phase 2 study that has completed, run by Cellerant Therapeutics. The registered enrollment target is 163 participants.
The verdict
NCT02282215, a Phase 2 study, has completed, sponsored by Cellerant Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra supportive care measure after induction chemotherapy for patients with acute myeloid leukemia (AML).
Interventions
- BIOLOGICAL G-CSF
- BIOLOGICAL CLT-008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02282215
The ClinicalTrials.gov registry entry for NCT02282215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellerant Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which G-CSF is the first listed.
NCT02282215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02282215 about?
NCT02282215 is a clinical study titled "Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia". The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra supportive care measure after induction chemotherapy for patients with acute myeloid leukemia (AML).
What is the current status of trial NCT02282215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2014-12. Estimated completion is 2017-09-22.
What interventions are being tested in trial NCT02282215?
The interventions under investigation include: G-CSF (BIOLOGICAL), CLT-008 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02282215?
This trial is sponsored by Cellerant Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.